Stay updated on Pyrotinib Combo in HR+/HER2- Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib Combo in HR+/HER2- Clinical Trial page.

Latest updates to the Pyrotinib Combo in HR+/HER2- Clinical Trial page
- Check6 days agoChange DetectedA new revision entry v3.3.2 was added to the Record History, and the prior revision v3.3.1 was removed.SummaryDifference0.1%

- Check13 days agoChange DetectedThe Record History now shows a new revision entry v3.3.1 and removes v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRemoved the government funding notice about NIH operational status from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check34 days agoChange DetectedThe latest version adds a Recruitment Status section to the record view, making current enrollment status visible alongside other study details. This enhances visibility of the trial's progress within the page.SummaryDifference0.1%

- Check63 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference13%

- Check70 days agoChange Detected- Updated recruitment status and study title to reflect a newer version (v3.1.0) and a current date (2025-09-25). - Indicates progression to Active, not recruiting, and a renamed study: 'Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer' from the prior title. - Removed older date (2024-11-04) and older revision (v3.0.2) to align with the new revision (v3.1.0).SummaryDifference5%

Stay in the know with updates to Pyrotinib Combo in HR+/HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib Combo in HR+/HER2- Clinical Trial page.